{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:32:16Z","timestamp":1773772336073,"version":"3.50.1"},"reference-count":45,"publisher":"Pleiades Publishing Ltd","issue":"1","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dokl Biochem Biophys"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>\n                      It is assumed that the risk of developing type 2 diabetes mellitus (T2DM) in patients with gout is influenced by both generally accepted risk factors and factors related to gout. The aim of the study was to evaluate the impact of various risk factors for T2DM in patients with gout. A total of 444 patients (49 women, 395\u00a0men) \u226518 years old with gout and without DM were included. The duration of observation was 5.66 [2.69; 7.64] years. To identify the factors associated with the risk of developing T2DM, multivariate logistic regression was used, which included sex; T2DM in relatives; insufficient physical activity; unbalanced diet; age\u00a0\u00a0\u2265 45\u00a0years; \u22654 attacks per year; presence of tophi; BMI \u226530 kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ; allopurinol, febuxostat, glucocorticoids, diuretics, metformin, colchicine; GFR &lt; 60 mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      ; serum uric acid level (sUA) \u2265 420\u00a0\u00b5mol\/L and \u00a0\u2265 480 \u00b5mol\/L. T2DM developed in 108 (24.3%) patients. According to the multivariate model, the presence of \u22654 attacks of arthritis per year increased the risk of T2DM (OR = 5.23; 95% CI: 2.98\u20139.19;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.0001); presence of tophi (OR = 2.61; 95% CI: 1.50\u20134.54;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.001); sUA \u2265 480 \u00b5mol\/L (OR = 2.26; 95% CI: 1.02\u20135.00;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.144); diuretics (OR = 2.35; 95% CI: 1.19\u20134.64;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.014). Febuxostat (OR\u00a0=\u00a00.31; 95% CI: 0.11\u20130.84;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.022) and metformin (OR = 0.49; 95% CI: 0.21\u20131.16;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.107) reduced the risk of developing T2DM. Risk of T2DM in patients with gout is associated with high incidence of arthritis attacks, MK \u2265 480 \u03bcmol\/L, hypertension, diuretic use, and febuxostat and metformin reduces risk.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1134\/s1607672923700321","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T17:01:41Z","timestamp":1697216501000},"page":"195-202","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Contributing Factors of Diabetes Mellitus among Patients with Gout (Results of the Long-Term Prospective Study)"],"prefix":"10.1134","volume":"511","author":[{"given":"O. V.","family":"Zheliabina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. S.","family":"Eliseev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. I.","family":"Glukhova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. L.","family":"Nasonov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"137","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"key":"7411_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11886-019-1107-y","volume":"21","author":"D Glovaci","year":"2019","unstructured":"Glovaci, D., Fan, W., and Wong, N.D., Epidemiology of diabetes mellitus and cardiovascular disease, Curr. Cardiol. Rep., 2019, vol. 21, no. 4, p. 21.","journal-title":"Curr. Cardiol. Rep."},{"key":"7411_CR2","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2174\/1570161117666190405165151","volume":"18","author":"M Viigimaa","year":"2020","unstructured":"Viigimaa, M., Sachinidis, A., Toumpourleka, M., Koutsampasopoulos, K., Alliksoo, S., and Titma, T., Macrovascular complications of type 2 diabetes mellitus, Curr. Vasc. Pharmacol., 2020, vol. 18, no. 2, p. 110\u2013116.","journal-title":"Curr. Vasc. Pharmacol."},{"key":"7411_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12916-017-0901-x","volume":"15","author":"H. Kolb","year":"2017","unstructured":"Kolb, H. and Martin, S., Environmental\/lifestyle factors in the pathogenesis and prevention of type 2 diabetes, BMC Med., 2017, vol. 15, no. 1, p. 131.","journal-title":"BMC Med."},{"key":"7411_CR4","first-page":"1582","volume":"31","author":"K.L. Wallace","year":"2004","unstructured":"Wallace, K.L., Riedel, A.A., Joseph-Ridge, N., and Wortmann, R., Increasing prevalence of gout and hyperuricemia\u00a0over 10 years among older adults in a managed care population, J. Rheumatol., 2004, vol. 31, no. 8, pp. 1582\u20131587.","journal-title":"J. Rheumatol."},{"key":"7411_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2217\/17584272.4.1.75","volume":"4","author":"A. Menon","year":"2009","unstructured":"Menon, A. and Roddy, E., Update on factors predisposing to gout, Int. J. Clin. Rheumatol., 2009, vol. 4, pp.\u00a075\u201387.","journal-title":"Int. J. Clin. Rheumatol."},{"key":"7411_CR6","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/BOR.0b013e3283438e13","volume":"23","author":"J.A. Singh","year":"2011","unstructured":"Singh, J.A., Reddy, S.G., and Kundukulam, J., Risk factors for gout and prevention: a systematic review of\u00a0the literature, Curr. Opin. Rheumatol., 2011, vol. 23, no. 2, pp. 192\u2013202.","journal-title":"Curr. Opin. Rheumatol."},{"key":"7411_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1136\/annrheumdis-2014-205827","volume":"75","author":"Y.H. Rho","year":"2016","unstructured":"Rho, Y.H., Lu, N., Peloquin, C.E., Man, A., Zhu, Y., Zhang, Y., et al., Independent impact of gout on the risk of diabetes mellitus among women and men: a population-based, BMI-matched cohort study, Ann. Rheum. Dis., 2016, vol. 75, no. 1, pp. 91\u201395.","journal-title":"Ann. Rheum. Dis."},{"key":"7411_CR8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/BOR.0b013e32835d951e","volume":"25","author":"C. Li","year":"2013","unstructured":"Li, C., Hsieh, M.C., and Chang, S.J., Metabolic syndrome, diabetes, and hyperuricemia, Curr. Opin. Rheumatol., 2013, vol. 25, no. 2, pp. 210\u2013216.","journal-title":"Curr. Opin. Rheumatol."},{"key":"7411_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12916-017-0890-9","volume":"15","author":"T. Bardin","year":"2017","unstructured":"Bardin, T. and Richette, P., Impact of comorbidities on\u00a0\u00a0gout and hyperuricaemia: an update on prevalence and\u00a0treatment options, BMC Med., 2017, vol. 15, no. 1, p. 123.","journal-title":"BMC Med."},{"key":"7411_CR10","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.2337\/diab.37.12.1595","volume":"37","author":"G.M. Reaven","year":"1988","unstructured":"Reaven, G.M., Banting lecture 1988. Role of insulin resistance\u00a0in human disease, Diabetes, 1988, vol. 37, no. 12, pp. 1595\u20131607.","journal-title":"Diabetes"},{"key":"7411_CR11","first-page":"25","volume":"78","author":"H. Vuorinen-Markkola","year":"1994","unstructured":"Vuorinen-Markkola, H. and Yki-J\u00e4rvinen, H., Hyperuricemia and insulin resistance, J. Clin. Endocrinol. Metab., 1994, vol. 78, no. 1, pp. 25\u201329.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"7411_CR12","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1159\/000484283","volume":"192","author":"C. King","year":"2018","unstructured":"King, C., Lanaspa, M.A., Jensen, T., Tolan, D.R., S\u00e1nchez-Lozada, L.G., and Johnson, R.J., Uric acid as a cause of the metabolic syndrome, Contrib. Nephrol., 2018, vol. 192, pp. 88\u2013102.","journal-title":"Contrib. Nephrol."},{"key":"7411_CR13","doi-asserted-by":"publisher","first-page":"e0179482","DOI":"10.1371\/journal.pone.0179482","volume":"12","author":"N. van der Schaft","year":"2017","unstructured":"van der Schaft, N., Brahimaj, A., Wen, K.X., Franco, O.H., and Dehghan, A., The association between serum uric acid and the incidence of prediabetes and type 2 diabetes mellitus: The Rotterdam Study, PLoS\u00a0One, 2017, vol. 12, no. 6, p. e0179482.","journal-title":"PLoS\u00a0One"},{"key":"7411_CR14","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.2337\/dc09-0288","volume":"32","author":"S. Kodama","year":"2009","unstructured":"Kodama, S., Saito, K., Yachi, Y., Asumi, M., Sugawara, A., Totsuka, K., et al., Association between serum uric acid and development of type 2 diabetes, Diabetes Care, 2009, vol. 32, no. 9, pp. 1737\u20131742.","journal-title":"Diabetes Care"},{"key":"7411_CR15","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/art.1780200320","volume":"20","author":"S.L. Wallace","year":"1977","unstructured":"Wallace, S.L., Robinson, H., Masi, A.T., Decker, J.L., McCarty, D.J., and Y\u00fc, T.F., Preliminary criteria for the classification of the acute arthritis of primary gout, Arthritis Rheum., 1977, vol. 20, no. 3, pp. 895\u2013900.","journal-title":"Arthritis Rheum."},{"key":"7411_CR16","first-page":"390","volume":"107","author":"G. Alberti","year":"1999","unstructured":"Alberti, G., A desktop guide to type 2 diabetes mellitus. European Diabetes Policy Group 1998\u20131999 International Diabetes Federation European Region, Exp. Clin. Endocrinol. Diabetes, 1999, vol. 107, no. 7, pp.\u00a0390\u2013420.","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"7411_CR17","unstructured":"Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech. Rep. Ser., 2000, vol. 894, pp. 1\u2013253."},{"key":"7411_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/art.22466","volume":"57","author":"H.K. Choi","year":"2007","unstructured":"Choi, H.K., Ford, E.S., Li, C., and Curhan, G., Prevalence of the metabolic syndrome in patients with gout: The Third National Health and Nutrition Examination Survey, Arthritis Rheum., 2007, vol. 57, no. 1, pp. 109\u2013115.","journal-title":"Arthritis Rheum."},{"key":"7411_CR19","doi-asserted-by":"publisher","first-page":"272","DOI":"10.2478\/s11536-009-0026-5","volume":"4","author":"J. Kowalski","year":"2009","unstructured":"Kowalski, J., Krzemi\u0144ska, A., Banach, M., Pawlicki, L., \u015aliwczy\u0144ska-Rodziewicz, D., and Barylski, M., The concentration of uric acid in patients with metabolic syndrome and cardiovascular diseases, Open Med., 2009, vol. 4, no. 3, pp. 272\u2013278.","journal-title":"Open Med."},{"key":"7411_CR20","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.metabol.2008.01.030","volume":"57","author":"X. Sui","year":"2008","unstructured":"Sui, X., Church, T.S., Meriwether, R.A., Lobelo, F., and Blair, S.N., Uric acid and the development of metabolic syndrome in women and men, Metabolism, 2008, vol. 57, no. 6, pp. 845\u2013852.","journal-title":"Metabolism"},{"key":"7411_CR21","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1093\/rheumatology\/ken305","volume":"47","author":"H.K. Choi","year":"2008","unstructured":"Choi, H.K., De Vera, M.A., and Krishnan, E., Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile, Rheumatology (Oxford), 2008, vol. 47, no. 10, pp. 1567\u20131570.","journal-title":"Rheumatology"},{"key":"7411_CR22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/art.38918","volume":"67","author":"S.C. Kim","year":"2015","unstructured":"Kim, S.C., Liu, J., and Solomon, D.H., Risk of incident diabetes in patients with gout: a cohort study, Arthritis Rheumatol., 2015, vol. 67, no. 1, pp. 273\u2013280.","journal-title":"Arthritis Rheumatol."},{"key":"7411_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11926-017-0688-y","volume":"19","author":"G.E. Thottam","year":"2017","unstructured":"Thottam, G.E., Krasnokutsky, S., and Pillinger, M.H., Gout and metabolic syndrome: a tangled web, Curr. Rheumatol. Rep., 2017, vol. 19, no. 10, p. 60.","journal-title":"Curr. Rheumatol. Rep."},{"key":"7411_CR24","doi-asserted-by":"publisher","first-page":"884","DOI":"10.2337\/dc17-1434","volume":"41","author":"X. Li","year":"2018","unstructured":"Li, X., Meng, X., Gao, X., Pang, X., Wang, Y., Wu, X., et al., Elevated serum xanthine oxidase activity is associated with the development of type 2 diabetes: a\u00a0\u00a0prospective cohort study, Diabetes Care, 2018, vol.\u00a041, no. 4, pp. 884\u2013890.","journal-title":"Diabetes Care"},{"key":"7411_CR25","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/jdi.12870","volume":"10","author":"S. Sunagawa","year":"2019","unstructured":"Sunagawa, S., Shirakura, T., Hokama, N., Kozuka, C., Yonamine, M., Namba, T., et al., Activity of xanthine oxidase in plasma correlates with indices of insulin resistance and liver dysfunction in patients with type 2 diabetes mellitus and metabolic syndrome: a pilot exploratory study, J. Diabetes Invest., 2019, vol. 10, no. 1, pp.\u00a094\u2013103.","journal-title":"J. Diabetes Invest."},{"key":"7411_CR26","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/rheumatology\/ker373","volume":"51","author":"H.M. Lai","year":"2012","unstructured":"Lai, H.M., Chen, C.J., Su, B.Y., Chen, Y.C., Yu, S.F., Yen, J.H., et al., Gout and type 2 diabetes have a mutual interdependent effect on genetic risk factors and\u00a0higher incidences. Rheumatology (Oxford), 2012, vol. 51, no. 4, pp. 715\u2013720.","journal-title":"Rheumatology"},{"key":"7411_CR27","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1136\/annrheumdis-2021-eular.3151","volume":"80","author":"O Sheliabina","year":"2021","unstructured":"Sheliabina, O., Eliseev, M., Novikova, A., and Chikina, M., POS1140. Risk factors for the development of diabetes mellitus in patients with gout according to a 6-year prospective follow-up study, Ann. Rheum. Dis., 2021, vol. 80, suppl. 1, p. 849.","journal-title":"Ann. Rheum. Dis."},{"key":"7411_CR28","first-page":"7","volume":"11","author":"M.S. Eliseev","year":"2005","unstructured":"Eliseev, M.S., Barskova, V.G., Nasonov, E.L., Zilov, A.V., and Nasonova, V.A., Features of gout occurring with type II diabetes mellitus, Clin. Gerontol., 2005, vol. 11, no. 4, pp. 7\u201313.","journal-title":"Clin. Gerontol."},{"key":"7411_CR29","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s00380-013-0386-2","volume":"29","author":"E. Oda","year":"2014","unstructured":"Oda, E., Serum uric acid is an independent predictor of metabolic syndrome in a Japanese health screening population, Heart Vessels, 2014, vol. 29, no. 4, pp. 496\u2013503.","journal-title":"Heart Vessels"},{"key":"7411_CR30","doi-asserted-by":"publisher","first-page":"709","DOI":"10.2337\/diacare.29.03.06.dc05-1465","volume":"29","author":"L. Niskanen","year":"2006","unstructured":"Niskanen, L., Laaksonen, D.E., Lindstr\u00f6m, J., Eriksson, J.G., Kein\u00e4nen-Kiukaanniemi, S., Ilanne-Parikka, P., et al., Serum uric acid as a harbinger of metabolic outcome in subjects with impaired glucose tolerance: The Finnish Diabetes Prevention Study, Diabetes Care, 2006, vol. 29, no. 3, pp. 709\u2013711.","journal-title":"Diabetes Care"},{"key":"7411_CR31","doi-asserted-by":"publisher","first-page":"R63","DOI":"10.1186\/ar2978","volume":"12","author":"M.A. Becker","year":"2010","unstructured":"Becker, M.A., Schumacher, H.R., Espinoza, L.R., Wells, A.F., MacDonald, P., Lloyd, E., et al., The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: The CONFIRMS\u00a0trial, Arthritis Res Ther., 2010, vol. 12, no.\u00a02, p. R63.","journal-title":"Arthritis Res Ther."},{"key":"7411_CR32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13075-018-1593-0","volume":"20","author":"L. Gunawardhana","year":"2018","unstructured":"Gunawardhana, L., Becker, M.A., Whelton, A., Hunt, B., Castillo, M., and Saag, K., Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: Phase II placebo-controlled study, Arthritis Res. Ther., 2018, vol. 20, no. 1, p. 99.","journal-title":"Arthritis Res. Ther."},{"key":"7411_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.14412\/1996-7012-2020-2-97-103","volume":"14","author":"M.N. Chikina","year":"2020","unstructured":"Chikina, M.N., Eliseev, M.S., and Zhelyabina, O.V., Practical application of national clinical guidelines for the management of gout (preliminary data), Modern Rheumatol. J., 2020, vol. 14, no. 2, pp. 97\u2013103.","journal-title":"Modern Rheumatol. J."},{"key":"7411_CR34","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00296-016-3612-2","volume":"37","author":"J. Meng","year":"2017","unstructured":"Meng, J., Li, Y., Yuan, X., and Lu, Y., Effects of febuxostat on insulin resistance and expression of high-sensitivity C-reactive protein in patients with primary gout, Rheumatol. Int., 2017, vol. 37, no. 2, pp. 299\u2013303.","journal-title":"Rheumatol. Int."},{"key":"7411_CR35","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.2337\/dc09-0625","volume":"32","author":"G. Zoppini","year":"2009","unstructured":"Zoppini, G., Targher, G., Negri, C., Stoico, V., Perrone, F., Muggeo, M., et al., Elevated serum uric acid concentrations independently predict cardiovascular mortality in type 2 diabetic patients, Diabetes Care, 2009, vol. 32, no. 9, pp. 1716\u20131720.","journal-title":"Diabetes Care"},{"key":"7411_CR36","doi-asserted-by":"publisher","first-page":"e27817","DOI":"10.1371\/journal.pone.0027817","volume":"6","author":"H. Ito","year":"2011","unstructured":"Ito, H., Abe, M., Mifune, M., Oshikiri, K., Antoku, S., Takeuchi, Y., et al., Hyperuricemia is independently associated with coronary heart disease and renal dysfunction in patients with type 2 diabetes mellitus, PLoS One, 2011, vol. 6, no. 11, p. e27817.","journal-title":"PLoS One"},{"key":"7411_CR37","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.biopha.2004.09.012","volume":"58","author":"M. Afshari","year":"2004","unstructured":"Afshari, M., Larijani, B., Rezaie, A., Mojtahedi, A., Zamani, M.J., Astanehi-Asghari, F., et al., Ineffectiveness of allopurinol in reduction of oxidative stress in diabetic patients; a randomized, double-blind placebo-controlled clinical trial, Biomed. Pharmacother., 2004, vol. 58, no. 10, pp. 546\u2013550.","journal-title":"Biomed. Pharmacother."},{"key":"7411_CR38","doi-asserted-by":"publisher","first-page":"e0210085","DOI":"10.1371\/journal.pone.0210085","volume":"14","author":"H.W. Chang","year":"2019","unstructured":"Chang, H.W., Lin, Y.W., Lin, M.H., Lan, Y.C., and Wang, R.Y., Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus, PLoS One, 2019, vol. 14, no. 1, p. e0210085.","journal-title":"PLoS One"},{"key":"7411_CR39","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.2337\/db15-0532","volume":"64","author":"R.J. Johnson","year":"2015","unstructured":"Johnson, R.J., Merriman, T., and Lanaspa, M.A., Causal or noncausal relationship of uric acid with diabetes, Diabetes, 2015, vol. 64, no. 8, pp. 2720\u20132722.","journal-title":"Diabetes"},{"key":"7411_CR40","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1097\/JIM.0000000000000242","volume":"63","author":"M. Takir","year":"2015","unstructured":"Takir, M., Kostek, O., Ozkok, A., Elcioglu, O.C., Bakan, A., Erek, A., et al., Lowering uric acid with allopurinol improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia, J. Invest. Med., 2015, vol. 63, no. 8, pp. 924\u2013929.","journal-title":"J. Invest. Med."},{"key":"7411_CR41","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa012512","volume":"346","author":"W.C. Knowler","year":"2002","unstructured":"Knowler, W.C., Barrett-Connor, E., Fowler, S.E., Hamman, R.F., Lachin, J.M., Walker, E.A., et al., Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention\u00a0or metformin, N. Engl. J. Med., 2002, vol.\u00a0346, no. 6, pp. 393\u2013403.","journal-title":"N. Engl. J. Med."},{"key":"7411_CR42","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1136\/annrheumdis-2018-214656","volume":"78","author":"N. Vazirpanah","year":"2019","unstructured":"Vazirpanah, N., Ottria, A., van der Linden, M., Wi-chers, C.G.K., Schuiveling, M., van Lochem, E., et al., mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: a prelude to a new add-on therapy?, Ann. Rheum. Dis., 2019, vol. 78, no. 5, pp. 663\u2013671.","journal-title":"Ann. Rheum. Dis."},{"key":"7411_CR43","first-page":"41","volume":"87","author":"V.G. Barskova","year":"2009","unstructured":"Barskova, V.G., Eliseev, M.S., Kudaeva, F.M., Aleksandrova, E.N., Volkov, A.V., Nasonova, V.A., et al., Effect of metformine on the clinical course of gout and\u00a0insulin resistance, Clin. Med., 2009, vol. 87, no. 7, pp. 41\u201346.","journal-title":"Clin. Med."},{"key":"7411_CR44","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3390\/ph13090234","volume":"13","author":"T. Salvatore","year":"2020","unstructured":"Salvatore, T., Pafundi, P.C., Galiero, R., Gjeloshi, K., Masini, F., Acierno, C., et al., Metformin: a potential therapeutic tool for rheumatologists, Pharmaceuticals (Basel), 2020, vol. 13, no. 9, p. 234.","journal-title":"Pharmaceuticals"},{"key":"7411_CR45","first-page":"628","volume":"93","author":"M.S. Eliseev","year":"2021","unstructured":"Eliseev, M.S., Panevin, T.S., Zhelyabina, O.V., and Nasonov, E.L., Advantages of the use of metformin in patients with impaired uric acid metabolism, Ter. Arkh., 2021, vol. 93, no. 5, pp. 628\u2013634.","journal-title":"Ter. Arkh."}],"updated-by":[{"DOI":"10.1134\/s1607672923050083","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000}}],"container-title":["Doklady Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S1607672923700321.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1134\/S1607672923700321","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S1607672923700321.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T15:16:48Z","timestamp":1773760608000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1134\/S1607672923700321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["7411"],"URL":"https:\/\/doi.org\/10.1134\/s1607672923700321","relation":{},"ISSN":["1607-6729","1608-3091"],"issn-type":[{"value":"1607-6729","type":"print"},{"value":"1608-3091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"20 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2024","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Erratum","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An Erratum to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1134\/S1607672923050083","URL":"https:\/\/doi.org\/10.1134\/S1607672923050083","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Conflict of interest\n                      . The authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"COMPLIANCE WITH ETHICAL STANDARDS"}},{"value":"Statement of compliance with standards of research involving humans as subjects\n                      . The study protocol was approved by the local ethics committee; all patients signed an informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"COMPLIANCE WITH ETHICAL STANDARDS"}}]}}